TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
This Quarter Return
-9.95%
1 Year Return
-56.28%
3 Year Return
-45.76%
5 Year Return
+44.93%
10 Year Return
–
AUM
$172M
AUM Growth
+$172M
(-18%)
Cap. Flow
-$4.52M
Cap. Flow
% of AUM
-2.63%
Top 10 Holdings %
Top 10 Hldgs %
57.79%
Holding
56
New
11
Increased
13
Reduced
11
Closed
13
Top Buys
| 1 |
Perrigo
PRGO
|
$8.11M |
| 2 |
United Therapeutics
UTHR
|
$7.07M |
| 3 |
Labcorp
LH
|
$5.86M |
| 4 |
Amgen
AMGN
|
$5.84M |
| 5 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
$5.19M |
Top Sells
| 1 |
Medtronic
MDT
|
$8.32M |
| 2 |
Merck
MRK
|
$7.29M |
| 3 |
CVS Health
CVS
|
$5.06M |
| 4 |
Exelixis
EXEL
|
$4.53M |
| 5 |
Gilead Sciences
GILD
|
$4.46M |
Sector Composition
| 1 | Healthcare | 95.35% |
| 2 | Consumer Staples | 2.99% |
| 3 | Technology | 0.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cigna
CI
$80.3B
| $16.6M | 9.61% | 63,000 -12,000 | -16% | -$3.16M |
|
2
Lantheus
LNTH
$3.73B
| $16.5M | 9.55% | 250,000 | – | – |
|
3
Cerus
CERS
$251M
| $10.6M | 6.12% | 2,000,000 +350,000 | +21% | +$1.85M |
|
4
Pacira BioSciences
PCRX
$1.2B
| $10.2M | 5.9% | 175,000 -30,000 | -15% | -$1.75M |
|
5
Tenet Healthcare
THC
$16.3B
| $8.41M | 4.87% | 160,000 +85,000 | +113% | +$4.47M |
|
|
MDRX
6
DELISTED
Veradigm Inc. Common Stock
MDRX
| $8.16M | 4.72% | 550,000 +350,000 | +175% | +$5.19M |
|
|
7
Perrigo
PRGO
$3.27B
| $8.11M | 4.69% | +200,000 | New | +$8.11M |
|
|
8
United Therapeutics
UTHR
$13.8B
| $7.07M | 4.09% | +30,000 | New | +$7.07M |
|
9
SI-BONE Inc
SIBN
$719M
| $7.06M | 4.09% | 535,000 +60,000 | +13% | +$792K |
|
|
10
Merck
MRK
$210B
| $6.84M | 3.96% | 75,000 -80,000 | -52% | -$7.29M |
|
11
AngioDynamics
ANGO
$417M
| $6.19M | 3.58% | 320,000 | – | – |
|
12
Phreesia
PHR
$1.88B
| $6.13M | 3.54% | 245,000 +70,000 | +40% | +$1.75M |
|
|
13
Labcorp
LH
$23.1B
| $5.86M | 3.39% | +25,000 | New | +$5.86M |
|
|
14
Amgen
AMGN
$155B
| $5.84M | 3.38% | +24,000 | New | +$5.84M |
|
15
Turning Point Brands
TPB
$1.79B
| $5.16M | 2.98% | 190,000 -10,000 | -5% | -$271K |
|
16
Bioventus
BVS
$495M
| $5.12M | 2.96% | 750,001 -75,000 | -9% | -$511K |
|
17
Sanofi
SNY
$121B
| $4.75M | 2.75% | +95,000 | New | +$4.75M |
|
18
AtriCure
ATRC
$1.84B
| $4.09M | 2.36% | 100,000 +35,000 | +54% | +$1.43M |
|
19
Jazz Pharmaceuticals
JAZZ
$7.75B
| $3.9M | 2.26% | 25,000 -5,000 | -17% | -$780K |
|
20
Viatris
VTRS
$12.3B
| $3.67M | 2.12% | 350,000 +125,000 | +56% | +$1.31M |
|
21
BioMarin Pharmaceuticals
BMRN
$11.2B
| $2.49M | 1.44% | +30,000 | New | +$2.49M |
|
22
Rigel Pharmaceuticals
RIGL
$697M
| $2.26M | 1.31% | 2,000,000 -1,250,000 | -38% | -$1.41M |
|
23
ICU Medical
ICUI
$3.15B
| $2.14M | 1.24% | +13,000 | New | +$2.14M |
|
|
ISEE
24
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $1.92M | 1.11% | 200,000 -170,000 | -46% | -$1.64M |
|
25
Collegium Pharmaceutical
COLL
$1.22B
| $1.77M | 1.03% | +100,000 | New | +$1.77M |
|